Cryptocurrency payment adoption by compounding pharmacies — need advice

julia.endo said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

carl_compliance said:

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Beyond-use dating (BUD) for compounded supply compounded products:

Lyophilized (unreconstituted): typically 6 months from compounding date
Reconstituted with BAC water: typically 28-30 days refrigerated
Reconstituted with sterile water: typically 24 hours (no preservative!)

Always use BAC water for multi-dose vials. Sterile water has no preservative and supports bacterial growth after first puncture. This is a common and potentially dangerous mistake.

Dr.GutHealth said:

A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.

Adding the part of the answer the thread has not reached. The trade-off is reversibility against privacy and there is no option that gives you both. Card payments are reversible and disclose the most; crypto discloses least and is irreversible, which is precisely why pressure toward it is a warning sign when it comes from a seller rather than a buyer. Escrow only means anything where the escrow agent is independent of both parties, which is rarely the case in practice.

Worth separating that from paying for it, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Following on from TirzTom — and this may be the naive question:

Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?

Closing the loop on my own question.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.